Physician profile
Meet Parikh
NPI 1942659578
$3,557.20
in general payments reported to CMS, 2019-2025
30 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $147 · 2021: $214 · 2022: $362 · 2023: $579 · 2024: $1,445 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Education: $30.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.77 |
| Education | $30.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.46 | 2020-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $230.51 | 2020-2024 | Stelara |
| Neurocrine Biosciences, INC. | $177.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.59 | 2021-2024 | Entyvio |
| Celgene Corporation | $172.12 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $166.77 | 2024 | Rezdiffra, Resmetirom |
| Covidien LP | $153.46 | 2019 | |
| Dova Pharmaceuticals | $124.53 | 2019 | |
| Akcea Therapeutics, INC. | $121.32 | 2019 | |
| Ardelyx, INC. | $117.81 | 2022-2025 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $100.52 | 2025 | Monoferric |
| Fujifilm Healthcare Americas Corporation | $92.20 | 2024 | Fujifilm |
| Erbe USA INC | $70.00 | 2024 | |
| Redhill Biopharma INC. | $55.36 | 2023-2024 | Talicia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $53.00 | 2023-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $48.35 | 2023-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $48.29 | 2024 | Voquezna |
| Lilly USA, LLC | $46.45 | 2024 | Omvoh |
| Capsovision, INC. | $39.57 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $37.77 | 2023-2025 | Ocaliva |
| Novo Nordisk INC | $37.12 | 2024 | Wegovy |
| Romark Laboratories, Lc | $33.54 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $32.57 | 2024 | Dupixent |
| Celltrion USA INC. | $30.93 | 2024 | Zymfentra |
| Genzyme Corporation | $30.93 | 2023-2024 | |
| Gilead Sciences, INC. | $29.90 | 2024 | |
| Braintree Laboratories, INC. | $19.16 | 2024 | Suflave, Sutab |
| Vivus LLC | $16.30 | 2025 | Pancreaze |
| Conmed Corporation | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meet Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.